Xbrane Biopharma AB Statistics
Total Valuation
STO:XBRANE has a market cap or net worth of SEK 213.27 million. The enterprise value is 239.78 million.
Important Dates
The last earnings date was Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
STO:XBRANE has 20.61 million shares outstanding. The number of shares has decreased by -98.94% in one year.
| Current Share Class | 20.61M |
| Shares Outstanding | 20.61M |
| Shares Change (YoY) | -98.94% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.42% |
| Owned by Institutions (%) | -1.54% |
| Float | 17.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 8.19 |
| PS Ratio | 1.67 |
| PB Ratio | 0.40 |
| P/TBV Ratio | 0.40 |
| P/FCF Ratio | 3.16 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 3.55 |
Financial Position
The company has a current ratio of 3.21, with a Debt / Equity ratio of 0.12.
| Current Ratio | 3.21 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.95 |
| Interest Coverage | -7.79 |
Financial Efficiency
Return on equity (ROE) is -11.10% and return on invested capital (ROIC) is -6.93%.
| Return on Equity (ROE) | -11.10% |
| Return on Assets (ROA) | -9.50% |
| Return on Invested Capital (ROIC) | -6.93% |
| Return on Capital Employed (ROCE) | -6.86% |
| Weighted Average Cost of Capital (WACC) | 7.58% |
| Revenue Per Employee | 4.57M |
| Profits Per Employee | -2.24M |
| Employee Count | 28 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 0.62 |
Taxes
In the past 12 months, STO:XBRANE has paid 89,000 in taxes.
| Income Tax | 89,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.12% in the last 52 weeks. The beta is 0.70, so STO:XBRANE's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | +9.12% |
| 50-Day Moving Average | 12.00 |
| 200-Day Moving Average | 10.00 |
| Relative Strength Index (RSI) | 40.19 |
| Average Volume (20 Days) | 219,986 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, STO:XBRANE had revenue of SEK 127.95 million and -62.68 million in losses. Loss per share was -3.04.
| Revenue | 127.95M |
| Gross Profit | 19.82M |
| Operating Income | -36.29M |
| Pretax Income | -61.76M |
| Net Income | -62.68M |
| EBITDA | -39.63M |
| EBIT | -36.29M |
| Loss Per Share | -3.04 |
Full Income Statement Balance Sheet
The company has 37.41 million in cash and 63.93 million in debt, with a net cash position of -26.52 million or -1.29 per share.
| Cash & Cash Equivalents | 37.41M |
| Total Debt | 63.93M |
| Net Cash | -26.52M |
| Net Cash Per Share | -1.29 |
| Equity (Book Value) | 527.15M |
| Book Value Per Share | 25.58 |
| Working Capital | 196.33M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -76.80 million and capital expenditures 144.30 million, giving a free cash flow of 67.50 million.
| Operating Cash Flow | -76.80M |
| Capital Expenditures | 144.30M |
| Depreciation & Amortization | -3.33M |
| Net Borrowing | 56.65M |
| Free Cash Flow | 67.50M |
| FCF Per Share | 3.28 |
Full Cash Flow Statement Margins
Gross margin is 15.49%, with operating and profit margins of -28.36% and -48.99%.
| Gross Margin | 15.49% |
| Operating Margin | -28.36% |
| Pretax Margin | -48.27% |
| Profit Margin | -48.99% |
| EBITDA Margin | -30.97% |
| EBIT Margin | -28.36% |
| FCF Margin | 52.76% |
Dividends & Yields
STO:XBRANE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 98.94% |
| Shareholder Yield | 98.94% |
| Earnings Yield | -29.39% |
| FCF Yield | 31.65% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on October 17, 2025. It was a reverse split with a ratio of 0.008.
| Last Split Date | Oct 17, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.008 |
Scores
STO:XBRANE has an Altman Z-Score of -0.1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.1 |
| Piotroski F-Score | n/a |